Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Budi EH, Schaub JR, Decaris M, Turner S, Derynck R (2021) TGF- as a driver of fibrosis: physiological roles and therapeutic opportunities
When patients discontinue weight loss injections, weight regain is common and well-documented in clinical studies
Lower plasma AST and ALT concentrations were the only parameters associated to the severity of steatosis and fibrosis at the end of the study, while changes in liver fibrosis scores (APRI, NFS, FIB-4, and AST/ALT ratio) showed limited value in predicting response to therapy
GLP-1 medications have demonstrated benefits for type 2 diabetes, cardiovascular disease risk reduction, kidney disease progression, and metabolic syndrome
For analysts performing GLP-1 impurity profiling, understanding the physics behind core-shell performance is essential for rational method development
US$ 20.98
US$ 20.14
US$ 21.09
US$ 28.31
US$ 22.03
US$ 27.87
US$ 21.97
